Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn ...
, opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...